dpDARSH PHARMALINKREGULATORY CONSULTANCY

OUR APPROACH

Specialist focus.
Accountable delivery.

Darsh Pharmalink is an independent regulatory consultancy supporting startups, biotech, pharmaceutical companies of all sizes and CRO partners with strategy, technical assessment and submission execution.

EXPERIENCE BEHIND THE WORK

Scientific judgement.
Operational understanding.

The consultancy draws on more than 15 years of regulatory affairs experience across global and regional roles, supported by an early foundation in process validation and Quality.

That experience spans small molecules, biologics, RNAi therapeutics and combination products, connecting dossier content with manufacturing, development and supply considerations.

Assignments are led by a principal consultant. The scope, responsible individuals and delivery arrangements are agreed at the outset.

HOW AN ASSIGNMENT WORKS

01

Establish the decision

Understand the product, evidence, markets and time constraints. Agree what the assignment needs to resolve.

02

Define the delivery

Set out scope, deliverables, responsibilities and dependencies, with realistic milestones and review points.

03

Keep the work accountable

Document recommendations, track unresolved issues and communicate decisions clearly to the relevant functions.

WORKING RELATIONSHIPS

Designed to complement
your existing team.

Support can focus on a single regulatory question or a defined programme workstream. Collaboration may include Development, Manufacturing, Quality, Supply Chain, CMOs, affiliates and local partners.

Detailed product information is shared under appropriate confidentiality arrangements. Initial enquiries should remain non-confidential.

Explore relevant experience →

PRODUCT EXPERTISE

Different products.
The same scientific rigour.

Regulatory support informed by experience across established medicines, innovative therapies and complex product presentations.

01

Small molecules

CMC submissions, manufacturing transfers and lifecycle strategy, including oral, parenteral and ophthalmic products.

02

Biologics

CMC strategy, dossier review and global lifecycle planning, including monoclonal antibodies.

03

RNAi therapeutics

International registration, partner coordination and lifecycle delivery for rare disease therapies.

04

Combination products

CMC planning that connects medicinal-product evidence, device-related input and implementation dependencies.

A CLEAR NEXT STEP

Contact our
experts today.

Discuss your requirements →